What We Do
Commitment to Innovation
Ocunova is developing a novel treatment for Dry Eye Syndrome. Unlike most lubricants, rewetting solutions and anti inflammatories, our therapy targets the specific type of Dry Eye the afflicts people with diabetes. Our novel eye drop solution is the subject of extensive research and is patent protected.
Clinical Development
Our novel compound (OCU-001) has been studied in multiple animal models and demonstrated safe in a phase 1 study. We are preparing to assess the safety and efficacy of OCU-001 in a human clinical study in the near future.
Compelling Data
Researchers from Penn State University have demonstrated in diabetic dry eye animal models that OCU-001 can quickly restore normal tear secretions and maintain normal tearing for up to 48 hours. Our scientists believe the unique mechanism of OCU-001 may help the millions of diabetics suffering with Dry Eye Syndrome